Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis

Luteolin (3′,4′,5,7-tetrahydroxyflavone), a member of the flavonoid family derived from plants and fruits, shows a wide range of biomedical applications. In fact, due to its anti-inflammatory, antioxidant and immunomodulatory activities, Asian medicine has been using luteolin for centuries to treat several human diseases, including arthritis, rheumatism, hypertension, neurodegenerative disorders and various infections. Of note, luteolin displays many anti-cancer/anti-metastatic properties. Thus, the purpose of this review consists in highlighting the relevant mechanisms by which luteolin inhibits tumor progression in metastasis, i.e., affecting epithelial-mesenchymal transition (EMT), repressing angiogenesis and lysis of extracellular matrix (ECM), as well as inducing apoptosis.

[1]  J. Kirkland Tumor dormancy and disease recurrence , 2023, Cancer and Metastasis Reviews.

[2]  B. Gălățeanu,et al.  Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions , 2023, International journal of molecular sciences.

[3]  A. Yezzi,et al.  Anti-Arthritic and Anti-Cancer Activities of Polyphenols: A Review of the Most Recent In Vitro Assays , 2023, Life.

[4]  M. Rizzo,et al.  A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study , 2023, Nutrients.

[5]  J. Sharifi‐Rad,et al.  Luteolin: a flavonoid with a multifaceted anticancer potential , 2022, Cancer Cell International.

[6]  R. Maestri,et al.  Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome , 2022, Clinical Neurophysiology.

[7]  M. Kumar,et al.  Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives , 2022, Cancers.

[8]  Shan Wu,et al.  Luteolin Suppresses Three Angiogenesis Modes and Cell Interaction in Uveal Melanoma in Vitro , 2022, Current eye research.

[9]  M. Brenner,et al.  Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study , 2022, Cells.

[10]  M. Brenner,et al.  Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial , 2022, Current neuropharmacology.

[11]  M. Brenner,et al.  Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial , 2022, Current Neuropharmacology.

[12]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[13]  Xiaoping Cai,et al.  Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways. , 2022, Tissue & cell.

[14]  S. Niland,et al.  Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression , 2021, International journal of molecular sciences.

[15]  H. Liao,et al.  Luteolin inhibits the proliferation, adhesion, migration and invasion of choroidal melanoma cells in vitro. , 2021, Experimental eye research.

[16]  M. Aschner,et al.  Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition , 2021, Medical Oncology.

[17]  K. Tomczak,et al.  Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing , 2021, Proceedings of the National Academy of Sciences.

[18]  G. Jayandharan,et al.  Vector engineering, strategies and targets in cancer gene therapy , 2021, Cancer Gene Therapy.

[19]  N. Tran,et al.  miRNA interplay: mechanisms and consequences in cancer , 2021, Disease models & mechanisms.

[20]  P. Bonadonna,et al.  Hypersensitivity reactions to chemotherapy: an EAACI Position Paper , 2021, Allergy.

[21]  A. Girotti,et al.  Advanced nanomedicine and cancer: challenges and opportunities in clinical translation. , 2021, International journal of pharmaceutics.

[22]  Shenglan Yang,et al.  EMT‐associated microRNAs and their roles in cancer stemness and drug resistance , 2021, Cancer communications.

[23]  V. Intasanta,et al.  Polymerized Luteolin Nanoparticles: Synthesis, Structure Elucidation, and Anti-Inflammatory Activity , 2021, ACS omega.

[24]  K. Bajbouj,et al.  Luteolin inhibits proliferation, triggers apoptosis and modulates Akt/mTOR and MAP kinase pathways in HeLa cells , 2021, Oncology letters.

[25]  Zhen Liu,et al.  The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway , 2021, Investigational New Drugs.

[26]  Dar-Ren Chen,et al.  Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[27]  I. Mackraj,et al.  The effect of hesperidin and luteolin isolated from Eriocephalus africanus on apoptosis, cell cycle and miRNA expression in MCF-7 , 2020, Journal of biomolecular structure & dynamics.

[28]  Yunbo Wei,et al.  Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis in vitro and in vivo. , 2020, Oncology reports.

[29]  Guo‐Yuan Zhu,et al.  Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  Anubhab Mukherjee,et al.  Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer , 2020, International journal of molecular sciences.

[31]  S. Sridhar,et al.  Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  T. Ko,et al.  Dietary Flavonoids Luteolin and Quercetin Inhibit Migration and Invasion of Squamous Carcinoma through Reduction of Src/Stat3/S100A7 Signaling , 2019, Antioxidants.

[33]  Xin‐an Zeng,et al.  Novel extraction techniques and pharmaceutical activities of luteolin and its derivatives. , 2019, Journal of food biochemistry.

[34]  M. Medina,et al.  The Mediterranean Diet, a Rich Source of Angiopreventive Compounds in Cancer , 2019, Nutrients.

[35]  B. Keikhaei,et al.  A review of molecular mechanisms involved in anticancer and antiangiogenic effects of natural polyphenolic compounds , 2019, Phytotherapy research : PTR.

[36]  G. Gao,et al.  Luteolin exhibits anti-breast cancer property through up-regulating miR-203 , 2019, Artificial cells, nanomedicine, and biotechnology.

[37]  Ajeet Singh,et al.  Synthesis of luteolin loaded zein nanoparticles for targeted cancer therapy improving bioavailability and efficacy , 2019, Journal of Drug Delivery Science and Technology.

[38]  F. Barber Adverse Events of Oncologic Immunotherapy and Their Management , 2019, Asia-Pacific journal of oncology nursing.

[39]  Jun Ren,et al.  A Review on the Antioxidative and Prooxidative Properties of Luteolin , 2019, Reactive Oxygen Species.

[40]  Yuanyuan Yao,et al.  Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR-384/pleiotrophin axis , 2019, Oncology reports.

[41]  M. Shariati,et al.  Luteolin, a flavonoid, as an anticancer agent: A review. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[42]  H. Lan,et al.  Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase , 2019, Oncology letters.

[43]  Qi Wang,et al.  HIF‐1α/VEGF signaling‐mediated epithelial–mesenchymal transition and angiogenesis is critically involved in anti‐metastasis effect of luteolin in melanoma cells , 2019, Phytotherapy research : PTR.

[44]  A. Sinha,et al.  Enhanced Induction of Apoptosis in HaCaT Cells by Luteolin Encapsulated in PEGylated Liposomes—Role of Caspase-3/Caspase-14 , 2018, Applied Biochemistry and Biotechnology.

[45]  K. Nakagawa,et al.  Absorption and Metabolism of Luteolin in Rats and Humans in Relation to in Vitro Anti-inflammatory Effects. , 2018, Journal of agricultural and food chemistry.

[46]  A. Cervantes,et al.  Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Tao Zhang,et al.  Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs , 2018, Journal of Cancer.

[48]  Rebecca J. Gryka,et al.  Luteolin Decreases Epidermal Growth Factor Receptor‐Mediated Cell Proliferation and Induces Apoptosis in Glioblastoma Cell Lines , 2018, Basic & clinical pharmacology & toxicology.

[49]  Minmin Wu,et al.  Luteolin inhibits angiogenesis of the M2‑like TAMs via the downregulation of hypoxia inducible factor‑1α and the STAT3 signalling pathway under hypoxia. , 2018, Molecular medicine reports.

[50]  Yun-Ru Chen,et al.  Stimulation of Fas/FasL‐mediated apoptosis by luteolin through enhancement of histone H3 acetylation and c‐Jun activation in HL‐60 leukemia cells , 2018, Molecular Carcinogenesis.

[51]  Matthew T. Cook Mechanism of metastasis suppression by luteolin in breast cancer , 2018, Breast cancer.

[52]  Cheng-Ying Chu,et al.  Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction , 2018, Journal of food and drug analysis.

[53]  Mian-hua Wu,et al.  Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p , 2018, International journal of molecular sciences.

[54]  D. Pinto,et al.  Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application , 2018, International journal of molecular sciences.

[55]  Kurexi Yunusi,et al.  Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma , 2017, Molecular medicine reports.

[56]  K. Kang,et al.  Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. , 2017, International journal of oncology.

[57]  Bingya Liu,et al.  Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer. , 2017, Biochemical and biophysical research communications.

[58]  Mohini Singh,et al.  EMT: Mechanisms and therapeutic implications , 2017, Pharmacology & therapeutics.

[59]  Chunying Gao,et al.  Pharmacokinetics, tissue distribution and excretion of luteolin and its major metabolites in rats: Metabolites predominate in blood, tissues and are mainly excreted via bile , 2017 .

[60]  Han-dong Wang,et al.  Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p-IGF-1R/PI3K/AKT/mTOR signaling pathway , 2017, Oncology letters.

[61]  H. Aisa,et al.  Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer , 2017, Oncology letters.

[62]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[63]  Chen Li,et al.  Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway , 2017, Journal of Translational Medicine.

[64]  J. Wan,et al.  Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. , 2017, Oncology reports.

[65]  C. Besch-Williford,et al.  Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. , 2016 .

[66]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[67]  L. Senggunprai,et al.  Luteolin induces cholangiocarcinoma cell apoptosis through the mitochondrial‐dependent pathway mediated by reactive oxygen species , 2016, The Journal of pharmacy and pharmacology.

[68]  Yongning Sun,et al.  Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301 , 2016, OncoTargets and therapy.

[69]  D. Trisciuoglio,et al.  Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies , 2016, Aging.

[70]  L. Wan,et al.  Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway , 2015, BMC Cancer.

[71]  Y. Shu,et al.  Luteolin Induces Apoptosis by Up-regulating miR-34a in Human Gastric Cancer Cells , 2015, Technology in cancer research & treatment.

[72]  A. Azmi,et al.  Broad targeting of angiogenesis for cancer prevention and therapy , 2015, Seminars in cancer biology.

[73]  A. Azmi,et al.  Tissue invasion and metastasis: Molecular, biological and clinical perspectives. , 2015, Seminars in cancer biology.

[74]  He-da Zhang,et al.  Luteolin Inhibits Breast Cancer Development and Progression In Vitro and In Vivo by Suppressing Notch Signaling and Regulating MiRNAs , 2015, Cellular Physiology and Biochemistry.

[75]  Mengtao Zhou,et al.  Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial–mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells , 2015, OncoTargets and therapy.

[76]  C. Besch-Williford,et al.  Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts , 2015, SpringerPlus.

[77]  Jie Cheng,et al.  The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer , 2015, Molecular oncology.

[78]  Zhongqi Li,et al.  Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer , 2015, Journal of Translational Medicine.

[79]  N. Peppas,et al.  Intelligent Nanoparticles for Advanced Drug Delivery in Cancer Treatment. , 2015, Current opinion in chemical engineering.

[80]  R. Derynck,et al.  Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. , 2014, Current opinion in cell biology.

[81]  D. Medici,et al.  Signaling mechanisms of the epithelial-mesenchymal transition , 2014, Science Signaling.

[82]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[83]  Tsung-Ying Yang,et al.  Luteolin attenuates TGF-β1-induced epithelial-mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt-NF-κB-Snail pathway. , 2013, Life sciences.

[84]  S. Jung,et al.  Raf and PI3K are the Molecular Targets for the Anti‐metastatic Effect of Luteolin , 2013, Phytotherapy research : PTR.

[85]  E. Zintzaras,et al.  An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. , 2013, Clinical therapeutics.

[86]  Xianglin Shi,et al.  Luteolin Inhibits Human Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis , 2012, PloS one.

[87]  A. Harris,et al.  How cancer metabolism is tuned for proliferation and vulnerable to disruption , 2012, Nature.

[88]  Xueting Cai,et al.  The molecular mechanism of luteolin-induced apoptosis is potentially related to inhibition of angiogenesis in human pancreatic carcinoma cells. , 2012, Oncology reports.

[89]  J. Matés,et al.  Oxidative stress in apoptosis and cancer: an update , 2012, Archives of Toxicology.

[90]  Yin Lu,et al.  Luteolin reduces the invasive potential of malignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition , 2012, Acta Pharmacologica Sinica.

[91]  Yin Lu,et al.  Inhibition of hypoxia-induced epithelial mesenchymal transition by luteolin in non-small cell lung cancer cells. , 2012, Molecular medicine reports.

[92]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[93]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[94]  H. Steller,et al.  Programmed Cell Death in Animal Development and Disease , 2011, Cell.

[95]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[96]  Xiaoyuan Chen,et al.  Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. , 2010, Current drug targets.

[97]  Anindya Dutta,et al.  MicroRNAs in cancer. , 2009, Annual review of pathology.

[98]  K. Watabe,et al.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. , 2008, Biochimica et biophysica acta.

[99]  S. Zeng,et al.  Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. , 2008, Journal of agricultural and food chemistry.

[100]  R. Weinberg,et al.  Adaptation versus selection: the origins of metastatic behavior. , 2007, Cancer research.

[101]  S. Elmore Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[102]  S. Belinsky,et al.  A Critical Role of Luteolin-Induced Reactive Oxygen Species in Blockage of Tumor Necrosis Factor-Activated Nuclear Factor-κB Pathway and Sensitization of Apoptosis in Lung Cancer Cells , 2007, Molecular Pharmacology.

[103]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[104]  M. Nair,et al.  From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer , 2006, Expert opinion on therapeutic targets.

[105]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[106]  L. Morbidelli,et al.  Luteolin Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis; Inhibition of Endothelial Cell Survival and Proliferation by Targeting Phosphatidylinositol 3′-Kinase Activity , 2004, Cancer Research.

[107]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[108]  M. Nair,et al.  Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. , 2002, Anticancer research.

[109]  S. De Flora,et al.  ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  E. De Clercq,et al.  Angiogenesis: regulators and clinical applications. , 2001, Biochemical pharmacology.

[111]  P. Basset,et al.  Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[112]  H. Liao,et al.  Effect of luteolin on apoptosis and vascular endothelial growth factor in human choroidal melanoma cells. , 2021, International journal of ophthalmology.

[113]  L. Fu,et al.  Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. , 2014, American journal of cancer research.

[114]  A. Pandurangan,et al.  Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/β-catenin/GSK-3β signaling. , 2013, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[115]  A. Azzariti,et al.  EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. , 2011, Frontiers in bioscience.

[116]  Paul C. Wang,et al.  Circumventing tumor resistance to chemotherapy by nanotechnology. , 2010, Methods in molecular biology.

[117]  M. López-Lázaro Distribution and biological activities of the flavonoid luteolin. , 2009, Mini reviews in medicinal chemistry.

[118]  G. Tuszynski,et al.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis , 2009, Pathology Oncology Research.

[119]  A. Tyner,et al.  Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[120]  V. Kim,et al.  Small RNAs : Classification , Biogenesis , and Function , 2005 .

[121]  J. Ross,et al.  Dietary flavonoids: bioavailability, metabolic effects, and safety. , 2002, Annual review of nutrition.